Abstract: A display device may include a first pixel, a second pixel, a first data line electrically connected to the first pixel, a second data line electrically connected to the second pixel and electrically insulated from the first data line, a first signal wire electrically connected to the first data line, a second signal wire electrically connected to the second data line, and a connecting wire electrically connecting the second data line to the second signal wire. The connecting wire may include a first section and a second section. The second section may be directly connected to the first section, may overlap the first pixel, may overlap the first data line, and may be oblique relative to each of the first data line and the second data line in a plan view of the display device.

Abstract: The present invention relates to a novel-structured nucleic acid complex having a blood-brain barrier penetration ability and a composition comprising same and, more specifically, to a nucleic acid complex in which a bioactive nucleic acid is complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, and to a composition for blood-brain barrier penetration comprising same. The nucleic acid complex according to the present invention can penetrate the blood-brain barrier at excellent efficiency, and especially, the conjugation of a drug into the nucleic acid complex increases the blood-brain barrier penetration ability of the drug, and thus is very useful in treatment or diagnosis of diseases.

Abstract: A method for producing CAR-M1 macrophages expressing a chimeric antigen receptor in vitro and in vivo includes using a conjugate of a non-viral gene delivery system and a chimeric antigen receptor gene. The CAR-M1 macrophages are produced in vivo by delivering genes encoding a chimeric antigen receptor and IFN-?, specifically to macrophages in the body, and thus does not require culturing and preparing an in-vitro cellular therapeutic agent, thus reducing the manufacturing costs of therapeutic agents. The CAR-M1 macrophages are a safer therapy since a non-viral vector is used, as compared to the production of CAR-M1 macrophages by gene delivery using a viral vector, and are a novel therapeutic candidate having the advantage of high anticancer efficiency for solid cancers, due to CAR-M1 macrophages in which intrinsic properties of macrophages infiltrating solid cancers and cancer cell phagocytosis are improved.

Abstract: The present invention relates to a pharmaceutical composition that is for treating pancreatic cancer and contains a nucleic acid complex as an active ingredient, and more specifically, to a pharmaceutical composition that is for preventing or treating pancreatic cancer and contains a nucleic acid complex in which a bioactive peptide nucleic acid, having a sequence binding to the KRAS gene, and a carrier peptide nucleic acid are complementarily bound. The nucleic acid complex according to the present invention has excellent cell permeability and intracellular activity, and can effectively inhibit the expression of the KRAS gene and subtype genes thereof, and is thus useful for the prevention or treatment of pancreatic cancer.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dementia, containing a nucleic acid complex in which a carrier peptide nucleic acid and a bioactive peptide nucleic acid having a sequence for binding to a NLRP3 gene are complementarily bound. The nucleic acid complex according to the present invention has a blood-brain barrier penetration ability and can effectively inhibit expression and phosphorylation of the protein of the NLRP3 gene and tau, which a lower-level gene, and thus is useful in the prevention or treatment of dementia.

Abstract: A nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease including the same, and a method of regulating target gene expression using the same, are described. The nucleic acid complex may include a bioactive nucleic acid, which includes a material for facilitating endosomal escape, and a carrier peptide nucleic acid, complementarily bound to each other, as useful in a composition for treating or diagnosing disease, or a composition for regulating target gene expression. Such nucleic acid complex may increase the stability of the bioactive nucleic acid, reduce loss of the bioactive nucleic acid, such as precipitation caused by self-aggregation, increase the intracellular delivery efficiency of the bioactive nucleic acid, and easily regulate target gene expression.

Abstract: The present invention provides a method for producing a PNA oligomer. More specifically, the method comprises a step for reacting a PNA block and a PNA block in a solution to produce a PNA oligomer, and thus a PNA oligomer of interest can be produced with remarkably improved purity and yield.

Abstract: The present invention relates to a composition for preventing or treating macular degeneration, containing a cell permeable nucleic acid complex as an active ingredient and, more specifically, to a pharmaceutical composition for preventing, ameliorating, or treating macular degeneration comprising, a cell-permeable nucleic acid complex containing a bioactive nucleic acid targeting an NLRP3 gene; and a carrier peptide nucleic acid which are complementarily bound to said bioactive nucleic acid, as an active ingredient. The cell permeable nucleic acid complex, in which the bioactive nucleic acid targeting the NLRP3 gene and the carrier peptide nucleic acid are complementarily bound to each other, according to the present invention, has high cell permeability and thus inhibits the expression of NLRP3 without direct injection, and thereby is useful for preventing, ameliorating, or treating macular degeneration.

Abstract: Disclosed are a method for analyzing a melting curve using bi-functional fluorescent PNA probes, a method for diagnosing microsatellite instability (MSI) using the same, and a kit for diagnosing microsatellite instability (MSI) using the same. More particularly, disclosed are a method for analyzing a melting curve, based on the structure of fluorescent PNA probes that bind with different binding forces depending on the number of base mutations deleted using the fluorescent PNA probes capable of specifically binding to regions where the same base is repeated, and a method for rapidly and accurately detecting and analyzing microsatellite instability (MSI) by detecting gene mutation of microsatellite markers caused by base deletion in regions where the same base is repeated using the analysis method and analyzing the number of base mutations thus obtained.

Abstract: The present invention relates to a modified PNA oligomer for detecting gene methylation. By using a PNA probe modified by introducing a methyl group-specific substituent to the gamma position, N-terminus or C-terminus of the PNA, the present invention may be used for a method for detecting using a difference in physical properties between a gene and a non-methylated gene caused by an interaction between the probe and methyl groups of the gene.

Abstract: The present invention relates to a method of detecting multiple targets based on a single detection probe, and more particularly to a method of detecting multiple targets by amplifying each target with primers including an SNP-containing tag sequence, hybridizing the amplification products with a single detection probe capable of binding to the tag sequences and designed such that melting temperatures are different from each other, and analyzing melting curves. A method of detecting multiple targets according to the present invention enables the detection of multiple targets using a single probe, and thus is useful for detecting multiple targets because false positives are reduced and multiple targets are detectable with high sensitivity and at a rapid rate.

Abstract: The present invention relates to a method for analyzing the presence or absence of aneuploidy of a target chromosome with high sensitivity, and a composition for detecting chromosomal aneuploidy, and more particularly to a method of identifying chromosomal aneuploidy by amplifying a control nucleotide sequence, located on a chromosome not associated with chromosomal aneuploidy, and a target nucleotide sequence located on a chromosome associated with chromosomal aneuploidy, by using the same primer, and then hybridizing the amplification products with an assay probe that differs by one or two nucleotides from the control nucleotide sequence and with an elimination probe that comprises part or all of a sequence of the assay probe, which hybridizes with the target nucleotide sequence or the control nucleotide sequence, the elimination probe having a higher binding affinity for the amplification products than the assay probe, and analyzing melting curves of the hybridization products.

Abstract: The present invention relates to a composition for preventing or treating skin diseases, comprising a skin-penetrating nucleic acid complex as an effective component, and more specifically, to a pharmaceutical composition or a cosmetic composition for preventing, alleviating, or treating atopic dermatitis, comprising a skin-penetrating nucleic acid complex in which a carrier peptide nucleic acid and a bioactive nucleic acid targeting TLR2 or IL-4R? are connected by complementary binding. The skin-penetrating nucleic acid complex according to the present invention, in which the carrier peptide nucleic acid and the bioactive nucleic acid targeting TLR2 or IL-4R? are connected by complementary binding, has high skin permeation and skin retention, and thus is useful in the prevention, alleviation or treatment of skin diseases such as atopic dermatitis.

Abstract: A skin-penetrating carrier containing a nucleic acid complex having a novel structure which introduces a bioactive nucleic acid into cells. Composition for diagnosing, preventing or treating disease and to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability. Skin-penetrating carrier containing nucleic acid complex having structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. Carrier enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, thus enables external treatment by application to the skin surface.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease comprising the same, and a method of regulating target gene expression using the same, and more particularly to a nucleic acid complex in which a bioactive nucleic acid, which comprises a material for facilitating endosomal escape, and a carrier peptide nucleic acid, are complementarily bound to each other, a composition for treating or diagnosing disease comprising the same, a composition for regulating target gene expression using the same, and a method of regulating target gene expression using the same.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which can introduce a bioactive nucleic acid into cells, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same, and more particularly to a nucleic acid complex comprising a bioactive nucleic acid complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same.

Abstract: Disclosed are a method for analyzing a melting curve using bi-functional fluorescent PNA probes, a method for diagnosing microsatellite instability (MSI) using the same, and a kit for diagnosing microsatellite instability (MSI) using the same. More particularly, disclosed are a method for analyzing a melting curve, based on the structure of fluorescent PNA probes that bind with different binding forces depending on the number of base mutations deleted using the fluorescent PNA probes capable of specifically binding to regions where the same base is repeated, and a method for rapidly and accurately detecting and analyzing microsatellite instability (MSI) by detecting gene mutation of microsatellite markers caused by base deletion in regions where the same base is repeated using the analysis method and analyzing the number of base mutations thus obtained.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which can introduce a bioactive nucleic acid into cells, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same, and more particularly to a nucleic acid complex comprising a bioactive nucleic acid complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same.

Abstract: A portable terminal is provided that includes a vibration generator for vibrating the portable terminal, a receiving device for receiving input from a user and determining a coordinate value on a display screen based on the received input, and a controller for determining a vibration pattern corresponding to information on a display screen based on the determined coordinate value.

Abstract: The present invention relates to a peptide nucleic acid (PNA) conjugated with multi-amine linkers, and a method to prepare the same and utilization thereof. More specifically, the method is characterized by conjugating monomers having multi-amine functionality sequentially at a PNA terminal, and effectively immobilizing the PNA conjugated with multi-amine linkers on a solid surface. A PNA array prepared using the PNA conjugated with multi-amine linkers exhibits improved sensitivity and specificity of signals for detecting target nucleic acids as compared to a PNA array using PNA probes having only one amine group. The PNA conjugated with multi-amine linkers can be utilized in nucleic acid detecting devices or kits for gene diagnosis such as PNA microarrays, PNA chips, PNA field-effect transistors and impedance detectors.